Identification of a Cytotoxic T-Lymphocyte Response to the Novel BARF0 Protein of Epstein-Barr Virus: a Critical Role for Antigen Expression

NORBERT KIENZLE, 1,* TOM B. SCULLEY, 1 LEITH POULSEN, 1 MARION BUCK, 1 SIMONE CROSS, 1 NANCY RAAB-TRAUB, 2 AND RAJIV KHANNA 1

EBV Unit, Queensland Institute of Medical Research, The Bancroft Centre, Herston, Queensland 4006, Australia, 1 and Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 2

Received 9 February 1998/Accepted 29 April 1998

The Epstein-Barr virus (EBV)-encoded BARF0 open reading frame gene products are consistently expressed in EBV-positive Burkitt’s lymphoma (BL) cell lines, nasopharyngeal carcinoma cell lines, and lymphoblastoid cell lines (LCLs). Here we show that the BARF0 sequence includes an HLA A*0201-restricted cytotoxic T-lymphocyte (CTL) epitope. By using theoretically predicted HLA A2 binding motifs and peptided-loaded antigen presentation-deficient T2 cells, polyclonal BARF0-specific CD8+ CTLs were isolated from four different healthy EBV-seropositive donors but not from two seronegative donors. These CTL lines recognized the peptide epitope LLWAARPRL, which was found to be conserved in 33 of 34 virus strains originating from Caucasian, African, and Asian individuals. The BARF0-specific CTL lines could lyse EBV-negative BL cells stably transfected with the BARF0 gene but did not kill HLA A2-matched EBV-positive BL cells and LCLs in a standard 51Cr release assay. Reverse transcriptase PCR analysis demonstrated that these EBV-positive cell lines expressed significantly lower levels of BARF0 mRNA than transfected cells. This data indicated that the BARF0 epitope could be endogenously processed; however, antigen levels in the target cell were a limiting factor for the effective interaction between BARF0-expressing cells and CTLs. The limited expression of BARF0 antigen in EBV-infected BL cells and LCLs might contribute to the escape of immune recognition from virus-specific CTLs present in the host.

Epstein-Barr virus (EBV) is a human gammaherpesvirus which infects at least 90% of the world’s population. EBV is the etiological agent of infectious mononucleosis and is associated with a variety of lymphoid and epithelial cancers, including Burkitt’s lymphoma (BL), nasopharyngeal carcinoma (NPC), and Hodgkin’s disease. After primary infection, EBV establishes a lifelong infection which is thought to be controlled primarily by EBV-specific cytotoxic T lymphocytes (CTLs) (reviewed in reference 27). The oncogenic potential of EBV is reflected in its ability to efficiently transform human B cells in vitro. The resulting latently infected lymphoblastoid cell lines (LCLs) express a restricted set of EBV genes, including those for six nuclear antigens (EBNA-1 to -6), three latent membrane proteins (LMP-1, LMP-2A, and LMP-2B) (reviewed in reference 15), and the novel gene products of the BARF0 open reading frame (ORF) (5). Three types of latency have been described for lymphoid cell lines and infected tissues (reviewed in reference 12). The pattern of latent gene expression present in latently infected LCLs and some BL cell lines is termed type III latency (5, 6, 9, 10). The BARF0-encoded proteins have become prime candidates for CTL-mediated recognition and killing of NPC and BL tumors. There is an increasing body of evidence that latent EBV infection is controlled primarily by HLA class I-restricted memory CTL responses. These can be reactivated in vitro by stimulating lymphocytes from EBV-seropositive donors with HLA-matched target cells presenting HLA class I- and II-restricted epitopes on the cell surface (reviewed in reference 12). Recently, we published a novel protocol for the identification of HLA-restricted CTL epitopes which led to the discovery of epitopes in LMP-1 (13). The protocol takes advantage of the peptide transporter (TAP)-negative T2 cell line, which is characterized by low HLA class I cell surface expression and impaired endogenous peptide presentation (30). HLA expression...
on T2 cells can be stabilized by exogenously delivered synthetic peptides, and these peptide-coated T2 cells can then be used to specifically stabilize memory CTLs. Using this approach, we have isolated CTLs specific for the BARF0 antigen from four different healthy EBV-seropositive individuals, and these BARF0-specific CTLs could recognize endogenously processed BARF0 protein expressed in a transfected EBV-negative BL cell line.

MATERIALS AND METHODS

Cell lines. The TAP-negative BxT hybrid cell line 1.74tCEM (referred to as T2) (30) was used for peptide stabilization assays. The EBV-positive BL cell lines Eli (29) and Mutul c59 (7) express latency type I EBV genes, and the BL cell line BL30 (18) and DG75 (2) are EBV-negative BL cell lines expressing a nonactivated, BL group I-like phenotype. LCLs were established by exogenous transformation of peripheral B cells (23). All cells were propagated biweekly in RPMI 1640 medium containing 2 mM glutamine, 60 μg of benzylpenicillin per ml, 100 μg of streptomycin per ml, and 10% fetal calf serum (growth medium) at 37°C in a 5% CO2 atmosphere.

Synthesis of peptides. Peptides with unblocked C and N termini were synthesized by the Merrifield solid phase method (Chrom Immotopes, Melbourne, Australia) on a peptide synthesizer and purified by HPLC. Five peptides containing these predicted motifs were then used in a standard HLA BARF0, the computer program HLA Peptide Binding Predictions was employed to evaluate peptide binding to the HLA A2 allele of the blood group I-like, EBV-negative human donor. All peptides were more than 95% pure as assessed by HPLC and mass spectrometry.

Establishment of polyclonal BARF0-specific CTLs and PHA blasts. Peripheral blood mononuclear cells (PBMC) from whole blood of HLA A*0201-positive human donors were separated on Ficoll-Paque, and polyclonal BARF0-specific CTL lines were generated from the PBMC as described recently (13). Briefly, T2 cells (5 × 10^6) were incubated with 100 μg of each of the peptides (50 to 100 μg/ml) for 14 to 16 h at 26°C, followed by incubation at 37°C for 2 to 3 h. HLA A2 expression on the peptide-coated T2 cells was then measured on a FACScan (Becton Dickinson, San Jose, Calif.) with an HLA A2-specific monoclonal antibody (MAb) (MA2.1, American Type Culture Collection) and an anti-mouse immunoglobulin G fluorescein isothiocyanate-conjugated antibody (Silenus, Victoria, Australia).

RESULTS

Generation of HLA A2-restricted BARF0-specific polyclonal CTL lines. In order to identify potential HLA A2-restricted CTL epitopes within the BARF0 ORF, the 174-amino-acid (aa) sequence of BARF0 (nucleotide residues 160477 to 160994 of the B95.8 strain [1]) was analyzed for HLA A*0201 peptide binding motifs by the method described recently by members of our laboratory (13). The two sequences LLSSLOQV and LLWAARPRL were identified as potential HLA A2 binding sites. To determine whether these sequences would bind to HLA A2, two overlapping 20-aa peptides (peptides 130 and 131) which corresponded to the BARF0 protein sequence and included the predicted sequences were synthesized and tested for HLA A2 binding efficiency by using T2 cells and an anti-HLA A2 MAb. Both peptides 130 (PPARADRALLWAPRLLS and 131 (WAARRLLLSSQVPEPRLA) (predicted sequences are underlined) significantly increased the expression of HLA A2 on T2 cells compared to untreated cells (Fig. 1). Peptide 130 stabilized HLA A2 expression to a similar strength as the B95.8 strain [1] was analyzed for HLA A*0201 peptide binding motifs by the method described recently by members of our laboratory (13). The two sequences LLSSLOQV and LLWAARPRL were identified as potential HLA A2 binding sites. To determine whether these sequences would bind to HLA A2, two overlapping 20-aa peptides (peptides 130 and 131) which corresponded to the BARF0 protein sequence and included the predicted sequences were synthesized and tested for HLA A2 binding efficiency by using T2 cells and an anti-HLA A2 MAb. Both peptides 130 (PPARADRALLWAPRLLS and 131 (WAARRLLLSSQVPEPRLA) (predicted sequences are underlined) significantly increased the expression of HLA A2 on T2 cells compared to untreated cells (Fig. 1). Peptide 130 stabilized HLA A2 expression to a similar strength as the B95.8 strain [1] was analyzed for HLA A*0201 peptide binding motifs by the method described recently by members of our laboratory (13). The two sequences LLSSLOQV and LLWAARPRL were identified as potential HLA A2 binding sites. To determine whether these sequences would bind to HLA A2, two overlapping 20-aa peptides (peptides 130 and 131) which corresponded to the BARF0 protein sequence and included the predicted sequences were synthesized and tested for HLA A2 binding efficiency by using T2 cells and an anti-HLA A2 MAb. Both peptides 130 (PPARADRALLWAPRLLS and 131 (WAARRLLLSSQVPEPRLA) (predicted sequences are underlined) significantly increased the expression of HLA A2 on T2 cells compared to untreated cells (Fig. 1). Peptide 130 stabilized HLA A2 expression to a similar strength as the B95.8 strain [1] was analyzed for HLA A*0201 peptide binding motifs by the method described recently by members of our laboratory (13). The two sequences LLSSLOQV and LLWAARPRL were identified as potential HLA A2 binding sites. To determine whether these sequences would bind to HLA A2, two overlapping 20-aa peptides (peptides 130 and 131) which corresponded to the BARF0 protein sequence and included the predicted sequences were synthesized and tested for HLA A2 binding efficiency by using T2 cells and an anti-HLA A2 MAb. Both peptides 130 (PPARADRALLWAPRLLS and 131 (WAARRLLLSSQVPEPRLA) (predicted sequences are underlined) significantly increased the expression of HLA A2 on T2 cells compared to untreated cells (Fig. 1).
against peptide-sensitized PHA blasts from an HLA A2-matched donor (LL). Representative data from polyclonal CTL cultures derived from three different donors (NK, LP, and AH) are illustrated in Fig. 2. All of the cultures stimulated by T2 cells coated with peptide 130 lysed peptide 130-coated PHA blasts but not PHA blasts coated with peptide 131 or untreated targets. In contrast, CTL cultures stimulated with T2 cells coated with peptide 131 did not recognize peptide 131-coated PHA blasts. This data indicated that peptide 130 but not peptide 131 included a CTL epitope. Surprisingly, CTLs from donor LP stimulated with T2 cells coated with peptide 131 showed some recognition of peptide 130-loaded PHA blasts. This recognition may have been due to the partially overlapping regions of peptide 131 and 130 sharing parts of the LLWAARPRL sequence. Although the predicted peptide specifically increased HLA B35 stabilization on T2 blasts. This recognition may have been due to the partially overlapping regions of peptide 131 and 130 sharing parts of the LLWAARPRL sequence. Although the predicted peptide specifically increased HLA B35 stabilization on T2 cells, stimulation of PBMC from an HLA B35-positive donor from donor LP stimulated with T2 cells coated with peptide 131 did not generate a significant CTL response (data not shown). This underlined the specificity of the HLA A2-restricted BARF0 CTL epitope.

**Definition of the minimal BARF0 CTL epitope.** To determine the minimal length of the CTL epitope present within peptide 130, overlapping peptides (9 to 12 aa long), which included the LLWAARPRLL sequence, were synthesized. These peptides were applied to PHA blasts and analyzed in a 51Cr release assay with an autologous polyclonal CTL line raised against peptide 130 from donor NK (referred to as NK-130). At standard peptide concentrations (>40 μg/ml), all of the BARF0 peptides containing the LLWAARPRLL epitope rendered effective killing of the targets (data not shown). In contrast, at limiting peptide concentrations, both the 9-mer LLWAARPRLL and the 10-mer LLWAARPRLLL were efficiently recognized by the NK-130 CTL line, while the 12-mer ALLWAARPRLLL and the 11-mer ALLWAARPRPLL elicited very low levels of CTL-mediated cell lysis. However, the peptide titration showed that the 9-mer LLWAARPRLL was the most active peptide (Fig. 3).

**EBV-seropositive, but not -seronegative, donors display a strong BARF0-specific CTL response.** To find out whether a BARF0-specific CTL response was present in seronegative individuals, PBMC of an EBV-negative but HLA A*0201-positive donor (KA) were stimulated with T2 cells sensitized with BARF0 peptide 130 or LLWAARPRPLL. For positive controls, PBMC of the EBV-positive donor NK were processed in parallel. After 17 days of culture, these polyclonal effector cells raised against peptide 130 or LLWAARPRPLL (referred to as KA-130, KA-LLW, NK-130, or NK-LLW) were analyzed against peptide-coated PHA blasts from donor NK in a standard 51Cr release assay. As illustrated in Fig. 4A, the CTL lines NK-130 and NK-LLW, both activated from the EBV-positive donor NK, specifically lysed the autologous NK PHA blasts sensitized with peptide 130 or LLWAARPRPLL but not NK PHA blasts coated with an HLA A2-restricted control peptide from LMP-1 (YLQQNWWTL) (13) or untreated targets. In contrast, the two CTL cultures (KA-130 and KA-LLW) originating from the seronegative donor KA did not significantly recognize the HLA A2-matched NK PHA blasts coated with either the BARF0 or the LMP-1 peptides. To confirm that both donors indeed had the same HLA A2 subtype, the reciprocal experiment was performed with KA PHA blasts as targets (Fig. 4A). Both BARF0-specific CTL lines of the seropositive donor (NK-130 and NK-LLW) strongly reacted with the BARF0 peptide (130 and LLWAARPRLL)-coated KA PHA

---

**FIG. 1.** HLA A2 stabilization analysis with T2 cells. T2 cells were either untreated (no peptide) or incubated with BARF0 peptide (pep.) 130 (PPRAR DRALLWAARPRLLLS) or 131 (WAARPRLLLSLQQVPEPRLA). For a positive control (pos. cont.), peptide YLLEMLWRL from LMP-1 was used. HLA A2 expression on these cells was then analyzed by using a FACScan and an HLA A2-specific MAb.

**FIG. 2.** Specificities of polyclonal BARF0-specific CTL lines. CTL lines derived from PBMC of the EBV-positive donor (NK, LP, and AH) were stimulated with T2 cells coated with peptide 130 loaded PHA blasts (from donor LL) which were either untreated or coated with BARF0 peptide 130 (PPRAR DRALLWAARPRLLLS) or 131 (WAARPRLLLSLQQVPEPRLA). Data from one representative experiment of three is presented. An E/T ratio of approximately 10:1 was used in the assay. The effectors were designated according to their donor origin and sensitizing peptide, e.g., NK-130 CTL indicates BARF0-specific CTLs from donor NK stimulated by peptide 130.

**FIG. 3.** Titration analysis for the minimal BARF0 epitope. 51Cr-labelled HLA A2-positive PHA blasts from donor NK were coated with different concentrations of overlapping 9-, 10-, 11-, or 12-aa-long peptide (all of which had the LLWAARPRLL sequence) and assayed for recognition by the autologous polyclonal NK-130 CTL line (E/T ratio, approximately 15:1). Representative results from one of two experiments are shown. Conc., Concentration.
BARF0-specific CTL response. Polyclonal CTL lines (effectors) derived from donors KA and RM were tested in a standard 51Cr release assay against HLA A2 PHA blasts as targets. For effector designations, see the legend to Fig. 2. An E/T ratio of either 16:1 (for NK-130/CTL and KA-130/CTL) or 13:1 (for NK-LLW/CTL, KA-LLW/CTL, JG-LLW/CTL, and RM-LLW/CTL) was used. (A) The PHA blasts (from donors NK and KA) were either untreated or coated with BARF0 peptide 130 (PPRARDRALLWAARPRLLLS) or LLWAARPRL (LLW). The effector cells were tested after 17 days of culture. (B) PHA blasts from donor RM were either untreated or coated with BARF0 peptide LLWAARPRL (LLW). For negative controls, the HLA A2-restricted peptide YLQQNWWTL (YLQ) from LMP-1 (13) was used. The effector cells were tested after 18 days of culture.

Blasts, in contrast to the case for the KA-130 and KA-LLW CTL cultures originating from the seronegative donor. Although the KA-LLW CTL culture showed some killing of the BARF0 peptide-coated targets, it was significantly (approximately threefold) lower than that of the NK CTL lines.

To confirm these results, a second EBV-seronegative HLA A*0201 donor (RM) was tested in parallel with a fourth seropositive donor (JG) or from the seronegative donor NK and JG or from the seronegative donor KA, in contrast to significant CTL-induced lysis from the seropositive donor NK. The precursors frequency of these BARF0-specific CTL clones was calculated as 1:534,956 to 1:538,750 with a 95% confidence limit. Although this frequency was very low, it was significant and in a range similar to that observed with the minimal CTL epitope YLQQNWWTTL of LMP-1 (13) when tested in parallel with peptide-coated T2 cells against PBMC of donor NK (data not shown).

To confirm the HLA A2 restriction of the epitope LLWAARPRL, an anti-class I antibody inhibition assay was performed with HLA A2-matched PHA blasts and the polyclonal CTL lines NK-130 and NK-LLW. Preincubation of LLWAARPRL-coated PHA blasts from donor LL with an anti-HLA class I MAb significantly reduced the specific lysis of these targets. Moreover, fluorescence-activated cell sorter analysis showed that both the NK-130 and NK-LLW CTL lines were primarily CD8 positive, with more than 75% of cells expressing both CD3 and CD8 and only 3 to 5% CD16- and CD56-positive LAK cells (data not shown). Taken together, this data identified the minimal BARF0 epitope as the 9-mer LLWAARPRL, which could reactivates an HLA A2-restricted CTL response in EBV-seropositive donors.

Characterization of the BARF0 epitope in EBV-infected BL cells, LCLs, and NPC biopsies. We and others have recently shown expression of the BARF0 ORF in a broad spectrum of EBV-infected cells (5, 6, 9, 10). This raised the question of whether EBV-positive cells could also endogenously process the LLWAARPRL epitope. A panel of HLA A2-matched BL cells expressing latency type I EBV genes (Eli and MutuI), a BL cell line of type III latency (MutuIII), and LCLs (SB, NK, and LL) were tested as targets in a standard 51Cr release assay with the BARF0-specific CTL line NK-130. Surprisingly, none of these targets appeared to be recognized and lysed (Fig. 5). This lack of CTL recognition of these targets was not due to a general impairment in their capacity to endogenously process antigen, since CTLs directed against another HLA A2-restricted epitope of EBV (from LMP-1) effectively lysed the BL and LCL targets (reference 13 and data not shown). Furthermore, exogenous addition of peptide LLWAARPRL to these target cells led to significant CTL-mediated lysis, whereas peptide-coated HLA A2-negative target cells (DM LCL and BL30) were not recognized (Fig. 5), thus the lack of CTL recognition of the EBV-positive cells was not due to impaired HLA A2 expression of the target cells.
Another possible explanation for the lack of CTL recognition of these EBV-positive cell lines could relate to strain variations in the BARF0 epitope expressed in these target cells. Therefore, the DNA region of BARF0 encoding the LLWAARPRL peptide was sequenced, but no sequence variation in this region was detected in these target cells. Moreover, a sequence analysis of a panel of 34 different virus isolates from three separate geographical areas showed a nearly perfect (except for one sample) conservation of the LLWAARPRLeptope (Table 1).

**TABLE 1. Sequence analysis of the HLA A2-restricted BARF0 CTL epitopes present in EBV isolates from different geographical regions**

<table>
<thead>
<tr>
<th>Reference strain or no. of isolates</th>
<th>Epitope sequence</th>
<th>Virus origin</th>
<th>HLA A2 frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B95.8</td>
<td>CTC CTC TGG GCC GCC CGG CCT CTT</td>
<td>Caucasianc</td>
<td>46</td>
</tr>
<tr>
<td>13</td>
<td>--- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---</td>
<td>Caucasianc</td>
<td>46</td>
</tr>
<tr>
<td>1</td>
<td>--- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---</td>
<td>Chinese</td>
<td>54</td>
</tr>
</tbody>
</table>

* The DNA and amino acid (boldface) sequences are compared to those of reference strain B95.8 (residues 160644 to 160670) (1). —, identity.

**DISCUSSION**

The latent persistent infection of EBV is controlled primarily by the HLA class I-restricted memory CTL response, and many EBV-associated neoplasms express viral antigens that can act as targets for CTL-mediated killing of these tumor cells. There is increasing evidence that most of the EBV-associated malignancies escape this potent virus-specific CTL response by restricting viral gene expression (reviewed in references 12 and 27). EBV-positive BL biopsies or NPCs express EBNA-1 and BARF0 or the combination of EBNA-1, LMP-1, LMP-2A, LMP-2B, and BARF0, respectively (5, 15). As EBNA-1 does not include HLA class I-restricted CTL epitopes (11, 19) and only a few HLA class I-restricted CTL epitopes are known to be included in LMP-1 (13), the novel BARF0 protein might be an important source of CTL epitopes for immunotherapeutic treatment of BL and NPC.

Indeed, this report presents, for the first time, evidence that the EBV-encoded BARF0 protein contains a CTL epitope and that EBV-positive individuals have an HLA A*0201-restricted CTL response to the 9-mer epitope LLWAARPRLe. Starting from theoretically predicted HLA class I binding motifs, peptides were synthesized and exogenously loaded onto antigen presentation-deficient T2 cells. The BARF0 peptide-coated T2 cells strongly activated in vitro polyclonal CTL lines from four healthy EBV-seropositive donors but not those from two seronegative individuals. The BARF0-specific CTL lines recognized the endogenously presented LLWAARPRLe epitope in transfected BL cells, indicating that this BARF0 CTL epitope is of biological relevance. The use of peptide-sensitized T2
cells is a very powerful approach to reactivate memory CTL responses; however, this method is also known to induce primary immune responses, as reported recently (32). Indeed, prolonged cultivation and repeated stimulation of the PBMC from the seronegative donor KA with peptide-sensitized T2 cells led to CTL cultures which killed BARF0 peptide-coated PHA blast targets (data not shown). So far, we do not know if this indicates the induction of a genuine primary immune response against the LLWAARPRL epitope or if this was due to a cross-reactivity in the in vitro cell cultures of the seronegative donor. However, the significant differences between the seropositive and seronegative donors in the time kinetics and recognition strengths of the stimulated BARF0 CTLs suggested that BARF0-specific CTLs were reactivated in EBV-positive donors from a memory response.

The HLA A2-restricted BARF0 epitope sequence was found to be conserved in 33 of 34 virus strains originating from Caucasian, African, and Asian individuals. Moreover, the HLA A2 allele has a high frequency in virtually all human populations (Table 1). This epitope therefore has the potential to be used in a CTL-based vaccine designed to control EBV-associated tumors such as Hodgkin’s disease and NPC. In contrast, this potential is limited in the case of BLs, as these tumors cannot endogenously process antigens due to downregulated HLA class I and TAP expression (28). In addition, BARF0-specific CTLs were unable to lyse EBV-positive BL cell lines, in contrast to peptide LLWAARPRL-loaded target cells and BARF0-transfected BL cells, all of which were killed. The encouraging observation that the BARF0-transfected cells could endogenously process the LLWAARPRL epitope implies that it was not an intrinsic BARF0 structure (as seen in the case of EBNA-1, in which antigen processing is prevented by internal repeats [19]) which inhibited HLA class I-restricted BARF0-specific CTL lysis of EBV-positive cells. Rather, this suggested that the amount of BARF0 protein present in the target cell might be important. Indeed, the RT-PCR data demonstrated lower levels of BARF0 mRNA expression in EBV-infected cells than in the BARF0 transfectants. Two recent papers reported the failure of HLA class I-restricted CTLs raised against EBNA antigens to lyse autologous EBV-infected cells (8, 31). Although these LCLs presented enough antigen to stimulate the outgrowth of CTL lines in vitro, both groups demonstrated that either superinfection with recombinant vaccinia virus encoding the appropriate target gene or incubation with the peptide epitope was necessary to detect lysis of the LCLs in a standard 51Cr release assay. As this assay is insensitive if fewer than 10 to 20% of the target cells express the antigen, the authors postulated that the amount of antigen presented on the EBV-positive cells may be heterogenous within the population of LCLs or BL cells. Since antigen density on the target cell seems to be a critical factor for the avidity of interaction between target cells and effector CTLs, it will be necessary to explore possible ways to increase BARF0 gene expression in EBV-positive BL cells and LCLs. It is tempting to speculate that the suboptimal expression of BARF0 antigen in these cells is a very powerful approach to reactivate memory CTL responses; however, this method is also known to induce primary immune responses, as reported recently (32). Indeed, prolonged cultivation and repeated stimulation of the PBMC from the seronegative donor KA with peptide-sensitized T2 cells led to CTL cultures which killed BARF0 peptide-coated PHA blast targets (data not shown). So far, we do not know if this indicates the induction of a genuine primary immune response against the LLWAARPRL epitope or if this was due to a cross-reactivity in the in vitro cell cultures of the seronegative donor. However, the significant differences between the seropositive and seronegative donors in the time kinetics and recognition strengths of the stimulated BARF0 CTLs suggested that BARF0-specific CTLs were reactivated in EBV-positive donors from a memory response.

The HLA A2-restricted BARF0 epitope sequence was found to be conserved in 33 of 34 virus strains originating from Caucasian, African, and Asian individuals. Moreover, the HLA A2 allele has a high frequency in virtually all human populations (Table 1). This epitope therefore has the potential to be used in a CTL-based vaccine designed to control EBV-associated tumors such as Hodgkin’s disease and NPC. In contrast, this potential is limited in the case of BLs, as these tumors cannot endogenously process antigens due to downregulated HLA class I and TAP expression (28). In addition, BARF0-specific CTLs were unable to lyse EBV-positive BL cell lines, in contrast to peptide LLWAARPRL-loaded target cells and BARF0-transfected BL cells, all of which were killed. The encouraging observation that the BARF0-transfected cells could endogenously process the LLWAARPRL epitope implies that it was not an intrinsic BARF0 structure (as seen in the case of EBNA-1, in which antigen processing is prevented by internal repeats [19]) which inhibited HLA class I-restricted BARF0-specific CTL lysis of EBV-positive cells. Rather, this suggested that the amount of BARF0 protein present in the target cell might be important. Indeed, the RT-PCR data demonstrated lower levels of BARF0 mRNA expression in EBV-infected cells than in the BARF0 transfectants. Two recent papers reported the failure of HLA class I-restricted CTLs raised against EBNA antigens to lyse autologous EBV-infected cells (8, 31). Although these LCLs presented enough antigen to stimulate the outgrowth of CTL lines in vitro, both groups demonstrated that either superinfection with recombinant vaccinia virus encoding the appropriate target gene or incubation with the peptide epitope was necessary to detect lysis of the LCLs in a standard 51Cr release assay. As this assay is insensitive if fewer than 10 to 20% of the target cells express the antigen, the authors postulated that the amount of antigen presented on the EBV-positive cells may be heterogenous within the population of LCLs or BL cells. Since antigen density on the target cell seems to be a critical factor for the avidity of interaction between target cells and effector CTLs, it will be necessary to explore possible ways to increase BARF0 gene expression in EBV-positive BL cells and LCLs. It is tempting to speculate that the suboptimal expression of BARF0 antigen in these cells is a very powerful approach to reactivate memory CTL responses; however, this method is also known to induce primary immune responses, as reported recently (32). Indeed, prolonged cultivation and repeated stimulation of the PBMC from the seronegative donor KA with peptide-sensitized T2 cells led to CTL cultures which killed BARF0 peptide-coated PHA blast targets (data not shown). So far, we do not know if this indicates the induction of a genuine primary immune response against the LLWAARPRL epitope or if this was due to a cross-reactivity in the in vitro cell cultures of the seronegative donor. However, the significant differences between the seropositive and seronegative donors in the time kinetics and recognition strengths of the stimulated BARF0 CTLs suggested that BARF0-specific CTLs were reactivated in EBV-positive donors from a memory response.

The HLA A2-restricted BARF0 epitope sequence was found to be conserved in 33 of 34 virus strains originating from Caucasian, African, and Asian individuals. Moreover, the HLA A2 allele has a high frequency in virtually all human populations (Table 1). This epitope therefore has the potential to be used in a CTL-based vaccine designed to control EBV-associated tumors such as Hodgkin’s disease and NPC. In contrast, this potential is limited in the case of BLs, as these tumors cannot endogenously process antigens due to downregulated HLA
EBV-infected cells might contribute to the escape of immune recognition from virus-specific CTLs present in the host.

On the other hand, very high levels of BARF0 RNA and protein expression have been observed in NPC (5, 6, 9), suggesting that BARF0-specific CTLs might be of immunotherapeutic value for the treatment of this malignancy. Moreover, NPC cells not only express TAP and HLA proteins, both of which are limiting factors in antigen presentation, but also display normal endogenous processing function and are efficiently recognized by virus-specific CTLs in vitro (14). It is important to mention here that our limiting-dilution assay data indicated that the CTL response to the BARF0 epitope constituted a minor component of the virus-specific CTL response in EBV-seropositive individuals. Nevertheless, the continuous presence of this CTL memory response implies constant exposure to endogenously processed BARF0 antigen. This could be occurring during the persistent stage of EBV infection, when the EBV latency proteins are expressed and presented to the immune system. Additionally, as the levels of BARF0 protein were shown to increase after induction of EBV viral replication (5), the low but continuous lytic cycle of EBV in healthy asymptomatic individuals could aid in the presentation of BARF0 antigen. If the high level of BARF0 expression in NPC cells renders them susceptible to lysis by BARF0-specific CTLs, it may be possible to amplify this component of the virus-specific CTL response by vaccination with the relevant peptide or to adoptively transfer BARF0-specific CTLs to control this common malignancy.

ACKNOWLEDGMENTS

We are grateful for the support of the members of the EBV unit at the Queensland Institute of Medical Research, particularly for technical and intellectual help provided by L. Morrison, S. R. Burrows, J. Whitson, and D. J. Moss, and we are indebted to the generosity of the Queensland Institute of Medical Research, particularly for technical support.

This work was supported by grants from the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund (OCF), and the Mayne Bequest, University of Queensland, Australia. R.K. is supported by an R.D. Wright fellowship from NHMRC.

REFERENCES